Targeted Therapies in Non Small Cell Lung Cancer
A continuing medical education activity sponsored by NAMCP and AAMCN

This activity is an archive of the live session held at the 2009 Fall Managed Care Forum.
If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from May 17, 2010 to December 31, 2010
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals


PLEASE CLICK HERE TO VIEW PRESENTATION

PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: View the presentation, answer the post test, complete the evaluation form, and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or you can fax them to Katie Eads at 804-747-5316.

Description
Despite progress in early detection and treatment, NSCLC is often diagnosed at an advanced stage and prognosis is poor. Historically, treatment has included a variety of modalities such as surgery, chemotherapy, and radiotherapy. More recently, therapeutic options for NSCLC have evolved to include targeted agents such as vinorelbine, paclitaxel, gemcitabine, docetaxel, pemetrexed, bevacizumab, and erlotinib. The expanding role of the targeted therapies and the concept of tailoring therapies based on clinical and molecular markers are transforming the treatment of NSCLC. It is imperative that oncologists, medical directors and nurses are informed about these new treatments and how they can be combined and used with current treatment regimens. During this session on non-small cell lung cancer, medical directors and nurse case managers will learn about these targeted therapies and the best way to include them into their treatment regimens.

Upon Completion of this activity, participants will be able to:

  • Identify advanced targeted therapy treatment regimens for patients with non small-cell lung cancer

  • Describe how targeted and traditional therapies for NSCLC can be integrated

  • Discuss how to incorporate the latest clinical trial data on targeted therapies into clinical practice

  • Review newly released NCCN Guidelines for lung cancer

  • Apply evidence-based guidelines to formulate targeted therapy treatment strategies for patients with late-stage NSCLC

  • Describe risk factors to consider in selecting the appropriate molecular-targeted agents for patients with advanced NSCLC

Faculty: Ramaswamy Govindan, MD
Director, Thoracic Medical Oncology
Alvin J. Siteman Cancer Center
Washington School of Medicine
St. Louis

Disclosure:

 Dr. Govindan is a consultant for ImClone, Pfizer, Lilly, and Astra Zeneca
  The NAMCP planning committee has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

  

This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals